Personalized Medicine Market By Product (Personalized Medicine Therapeutics, Personalized Medicine Diagnostics), By Application (Oncology, Infectious disease, Neurology or Psychiatry, Cardiovascular, Others), By End User (Hospitals and Clinics, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031

Personalized Medicine Market

The personalized medicines market is likely to experience a significant growth rate of 11.2% from 2022-2031 owing to increasing market demand from pharmaceutical sector –  

Personalized medicine is a type of treatment which focuses on the distinctive physiological characteristics of individual patient. Personalized medicine has a huge potential to change and adapt the healthcare industry with a special emphasis on disease diagnosis and management using analytics tools, customized medicines, clinical information, and other alternatives. Personalized medicines are used in diagnosis and treatment of various disorders such as cancer, respiratory disorders, cardiovascular disorders and other rare diseases. 

Rise in prevalence of chronic diseases, rise in awareness about precision medicines among people, and increase in R&D activities to develop new personalized medicines, are the major factors contributing to the growth of personalized medicine market. In addition, surge in demand for personalized medicines among the population is also driving the growth of market. This surge in demand for personalized medicines is attributed to the advances in genetic sequencing and data analytics which have made it possible to analyze a patient's DNA and identify specific genetic mutations that may cause a disease. This information can be used to develop personalized treatments that target the specific genetic cause of a disease. Furthermore, chronic diseases such as cancer, diabetes, and heart disease are becoming more common, and personalized medicine offers the potential for more effective treatments for these conditions. Thus, have a huge demand in the healthcare sector. 

Moreover, the surge in demand for personalized medicine reflects a growing recognition that a one-size-fits-all approach to healthcare is often less effective and less efficient. By tailoring treatments to individual patients, personalized medicine has the potential to improve patient outcomes, reduce healthcare costs, and transform the way of treatment. This further fosters the market growth. 

The personalized medicines market is expected to grow significantly in the coming years, by presenting various opportunities for key players in the industry. Key players may invest in developing innovative personalized medicine solutions that cater to a wider range of diseases and conditions. This can involve investing in research and development to improve drug discovery and development, as well as the development of companion diagnostics and biomarkers. In addition, key players can expand the geographic reach by expanding into new regions and markets. This can involve establishing partnerships or collaborations with local players or acquiring companies that have a strong presence in major regions. Also, key players may establish partnerships with healthcare providers to promote the adoption of personalized medicine. This can involve offering training and support to healthcare providers, as well as providing educational resources to patients and healthcare professionals. Such opportunities offered by the personalized medicine market to the key players is anticipated to boost the market during the forecast period. 

The global personalized medicine market is segmented based on product, application, end user and region. By product, the market is categorized into personalized medicine diagnostics and personalized medicine therapeutics. On the basis of application, market is segmented into oncology, neurology/psychiatry, infectious disease, cardiovascular and others. On the basis of end user, the market is segmented into hospitals & clinics, and others. Region wise, it is studied across North America (U.S., Canada and Mexico), Europe (France, UK, Germany, Italy, Spain, and rest of Europe, Asia-Pacific (China, Japan, Australia, and rest of Asia-Pacific, and LAMEA (Latin America and Middle East & Africa). 

The key players profiled in the study include Aadi Bioscience, Inc., Abbott Laboratories, ARIEL Precision Medicine, Inc., Hoffmann-La Roche Ltd, GE Healthcare, Illumina, Inc., Takeda Pharmaceutical Company Ltd, Eli Lilly and Company, Abbvie Inc. and Qiagen. The players in the market have been actively engaged in the adoption various strategies such as acquisition, collaboration, branding, product development, expansion, clinical trials, agreement, partnership, product launch, product approval and others to remain competitive and gain advantage over the competitors in the market. For instance, in December 2021, Qiagen announced a collaboration with Denovo Biopharma LLC to develop a blood-based companion diagnostic (CDx) test to identify patients expressing Denovo Genomic Marker 1 (DGM1TM) for treatment of diffuse large B-cell lymphoma (DLBCL), one of the most common lymphoid cancers, further strengthening its leading position in precision medicine. 

Key Market Insights (Updated) 

By product, the personalized medicine diagnostics segment was the highest revenue contributor to the market and is estimated to reach $479.5 billion by 2031, with a CAGR of 11.6%. Also, the same segment is estimated to be the fastest-growing segment during the forecast period. 

By application, the oncology segment dominated the global market. However, the cardiovascular segment is expected to be the fastest-growing segment during the forecast period. 

By end user, the hospitals and clinics segment was the highest revenue contributor to the market with a CAGR of 10.8% during the forecast period. On the other hand, the others segment is anticipated to grow at a fastest rate during the forecast period.  

Based on region, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period. 

Overview

The personalized medicine market valued for $300.00 billion in 2021 and is estimated to reach $869.48 billion by 2031, exhibiting a CAGR of 11.2% from 2022 to 2031. 

Personalized medicines are the medical treatment regime decided based on individual characteristics of each patient. The major factor determining whether an individual is susceptible to a particular disease is their molecular and genetic profile. Also, it makes it easier to estimate which treatments would be beneficial and safe for the patient. In some instances, tailored medications are also referred to as stratified or precision medications. The practice of personalized medicine is still in its development phase, but it already has applications in the prevention and diagnosis of some diseases in addition to helping determine the course of treatment. The key component of personalized medicine is the presence of biomarkers, which are indicators of infection, disease, or environmental exposure. For instance, blood cholesterol level is the biomarker which indicates the presence of coronary heart diseases. 

As traditional medicines do not have similar effect on each individual, owing to the differences in the genetic structures. Even small differences in the genetic structure may lead to unintended circumstances, and hence, this leads to the development of personalized medicines. In addition, personalized medicines offer several advantages such as improvement in disease detection, customization in disease-prevention strategies, provides more effective prescription drug use, prevention of predictable side effects and reduction in time and cost. Thus, such advantages lead to the increase in demand for personalized medicines, thereby propelling the growth of the market.

Furthermore, rise in prevalence of chronic conditions such as cancer, melanoma, and cardiovascular disease, and increase in demand for rapid action treatment procedure is increasing the demand for personalized medicines, and driving growth of the market. Also, surge in use of combination therapies, and increase in geriatric population are some of the factors that are driving the growth of personalized medicines market. The combination therapies use multiple drugs that work together to target different molecular mechanisms of the disease, and they are often tailored to each patient's unique genetic and molecular characteristics. Moreover, advantages offered by personalized medicines over the traditional medicines along with rise in adoption of these medicines is also driving the market growth. 

In addition, increase in R&D activities in the field of diagnosis is indeed a major factor driving the growth of the personalized medicine market. With advances in genomic sequencing, bioinformatics, and other technologies, researchers are now able to identify genetic variations and other biomarkers associated with specific diseases at the individual level. This has led to the development of new personalized diagnostic approaches and tests, including companion diagnostics (CDx), which are used to determine the suitability of a particular therapy for a specific individual. This boosts the growth of the personalized medicine market.

In addition, advancements in genomics and proteomics is further boosting the market growth. The rapid progress in genomics and proteomics has allowed for the identification of disease biomarkers, which are specific molecules or characteristics that indicate the presence of a disease or a predisposition to developing a disease. By identifying these biomarkers, researchers and medical professionals can gain insights into the underlying mechanisms of the disease, as well as develop targeted therapies that are tailored to the individual patient's genetic makeup and specific biomarker profile. Thus, advances in genomics and proteomics have revolutionized the treatment and hold a great promise for improving the diagnosis, treatment, and prevention of a wide range of diseases which augments the market growth.

However, high cost of personalized medicines hinders the growth of the personalized medicine market. High cost of diagnosis and treatment makes it inaccessible for the patients with poor financial conditions and restrain the market in developing regions. Furthermore, many patients are unaware of about the concept of personalized medicines, which acts as a restrain to the market. On the other hand, government and non-government organizations are creating awareness about the advanced healthcare options among the population, which may increase the adoption of personalized medicines, thus, driving the market during the forecast period. 

The global personalized medicine market is segmented based on product, application, end user and region. By product, the market is categorized into personalized medicine diagnostics and personalized medicine therapeutics. Based on application, market is segmented into oncology, neurology/psychiatry, infectious disease, cardiovascular and others. Based on end user, the market is segmented into hospitals & clinics, and others. Region wise, it is studied across North America (U.S., Canada, and Mexico), Europe (France, UK, Germany, Italy, Spain, and rest of Europe, Asia-Pacific (China, Japan, Australia, and rest of Asia-Pacific, and LAMEA (Latin America and Middle East & Africa).

Some of the major companies that operate in the global personalized medicine market are Aadi Bioscience, Inc., Abbott Laboratories, ARIEL Precision Medicine, Inc., Hoffmann-La Roche Ltd, GE Healthcare, Illumina, Inc., Takeda Pharmaceutical Company Ltd, Eli Lilly and Company, AbbVie Inc. and Qiagen. 

 

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the personalized medicine market analysis from 2021 to 2031 to identify the prevailing personalized medicine market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the personalized medicine market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global personalized medicine market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

○ Aadi Bioscience, Inc

Scope of Personalized Medicine Market Report

1.1. Report description

1.2. Key market segments

1.3. Key benefits to the stakeholders

1.4. Research Methodology

1.4.1. Primary research

1.4.2. Secondary research

1.4.3. Analyst tools and models

2.1. CXO Perspective

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top impacting factors

3.2.2. Top investment pockets

3.3. Porter’s five forces analysis

3.3.1. Bargaining power of suppliers

3.3.2. Bargaining power of buyers

3.3.3. Threat of substitutes

3.3.4. Threat of new entrants

3.3.5. Intensity of rivalry

3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Surge in demand for personalized medicines

3.4.1.2. Rise in prevalence of Cancer

3.4.1.3. Rise in prevalence of chronic conditions in the population

3.4.2. Restraints

3.4.2.1. High cost of personalized medicines

3.4.2.2. Lack of awareness regarding personalized medicines among population

3.4.3. Opportunities

3.4.3.1. Increase in healthcare expenditure with improvements in healthcare facilities

3.4.3.2. Technological advancements in personalized medicines

3.5. COVID-19 Impact Analysis on the market

4.1. Overview

4.1.1. Market size and forecast

4.2. Personalized Medicine Therapeutics

4.2.1. Key market trends, growth factors and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market share analysis by country

4.2.4. Personalized Medicine Therapeutics Personalized Medicine Market by Type

4.3. Personalized Medicine Diagnostics

4.3.1. Key market trends, growth factors and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market share analysis by country

5.1. Overview

5.1.1. Market size and forecast

5.2. Oncology

5.2.1. Key market trends, growth factors and opportunities

5.2.2. Market size and forecast, by region

5.2.3. Market share analysis by country

5.3. Infectious disease

5.3.1. Key market trends, growth factors and opportunities

5.3.2. Market size and forecast, by region

5.3.3. Market share analysis by country

5.4. Neurology or Psychiatry

5.4.1. Key market trends, growth factors and opportunities

5.4.2. Market size and forecast, by region

5.4.3. Market share analysis by country

5.5. Cardiovascular

5.5.1. Key market trends, growth factors and opportunities

5.5.2. Market size and forecast, by region

5.5.3. Market share analysis by country

5.6. Others

5.6.1. Key market trends, growth factors and opportunities

5.6.2. Market size and forecast, by region

5.6.3. Market share analysis by country

6.1. Overview

6.1.1. Market size and forecast

6.2. Hospitals and Clinics

6.2.1. Key market trends, growth factors and opportunities

6.2.2. Market size and forecast, by region

6.2.3. Market share analysis by country

6.3. Others

6.3.1. Key market trends, growth factors and opportunities

6.3.2. Market size and forecast, by region

6.3.3. Market share analysis by country

7.1. Overview

7.1.1. Market size and forecast By Region

7.2. North America

7.2.1. Key trends and opportunities

7.2.2. Market size and forecast, by Product

7.2.3. Market size and forecast, by Application

7.2.4. Market size and forecast, by End User

7.2.5. Market size and forecast, by country

7.2.5.1. U.S.

7.2.5.1.1. Key market trends, growth factors and opportunities

7.2.5.1.2. Market size and forecast, by Product

7.2.5.1.3. Market size and forecast, by Application

7.2.5.1.4. Market size and forecast, by End User

7.2.5.2. Canada

7.2.5.2.1. Key market trends, growth factors and opportunities

7.2.5.2.2. Market size and forecast, by Product

7.2.5.2.3. Market size and forecast, by Application

7.2.5.2.4. Market size and forecast, by End User

7.2.5.3. Mexico

7.2.5.3.1. Key market trends, growth factors and opportunities

7.2.5.3.2. Market size and forecast, by Product

7.2.5.3.3. Market size and forecast, by Application

7.2.5.3.4. Market size and forecast, by End User

7.3. Europe

7.3.1. Key trends and opportunities

7.3.2. Market size and forecast, by Product

7.3.3. Market size and forecast, by Application

7.3.4. Market size and forecast, by End User

7.3.5. Market size and forecast, by country

7.3.5.1. Germany

7.3.5.1.1. Key market trends, growth factors and opportunities

7.3.5.1.2. Market size and forecast, by Product

7.3.5.1.3. Market size and forecast, by Application

7.3.5.1.4. Market size and forecast, by End User

7.3.5.2. France

7.3.5.2.1. Key market trends, growth factors and opportunities

7.3.5.2.2. Market size and forecast, by Product

7.3.5.2.3. Market size and forecast, by Application

7.3.5.2.4. Market size and forecast, by End User

7.3.5.3. UK

7.3.5.3.1. Key market trends, growth factors and opportunities

7.3.5.3.2. Market size and forecast, by Product

7.3.5.3.3. Market size and forecast, by Application

7.3.5.3.4. Market size and forecast, by End User

7.3.5.4. Italy

7.3.5.4.1. Key market trends, growth factors and opportunities

7.3.5.4.2. Market size and forecast, by Product

7.3.5.4.3. Market size and forecast, by Application

7.3.5.4.4. Market size and forecast, by End User

7.3.5.5. Spain

7.3.5.5.1. Key market trends, growth factors and opportunities

7.3.5.5.2. Market size and forecast, by Product

7.3.5.5.3. Market size and forecast, by Application

7.3.5.5.4. Market size and forecast, by End User

7.3.5.6. Rest of Europe

7.3.5.6.1. Key market trends, growth factors and opportunities

7.3.5.6.2. Market size and forecast, by Product

7.3.5.6.3. Market size and forecast, by Application

7.3.5.6.4. Market size and forecast, by End User

7.4. Asia-Pacific

7.4.1. Key trends and opportunities

7.4.2. Market size and forecast, by Product

7.4.3. Market size and forecast, by Application

7.4.4. Market size and forecast, by End User

7.4.5. Market size and forecast, by country

7.4.5.1. Japan

7.4.5.1.1. Key market trends, growth factors and opportunities

7.4.5.1.2. Market size and forecast, by Product

7.4.5.1.3. Market size and forecast, by Application

7.4.5.1.4. Market size and forecast, by End User

7.4.5.2. China

7.4.5.2.1. Key market trends, growth factors and opportunities

7.4.5.2.2. Market size and forecast, by Product

7.4.5.2.3. Market size and forecast, by Application

7.4.5.2.4. Market size and forecast, by End User

7.4.5.3. Australia

7.4.5.3.1. Key market trends, growth factors and opportunities

7.4.5.3.2. Market size and forecast, by Product

7.4.5.3.3. Market size and forecast, by Application

7.4.5.3.4. Market size and forecast, by End User

7.4.5.4. Rest of Asia-Pacific

7.4.5.4.1. Key market trends, growth factors and opportunities

7.4.5.4.2. Market size and forecast, by Product

7.4.5.4.3. Market size and forecast, by Application

7.4.5.4.4. Market size and forecast, by End User

7.5. LAMEA

7.5.1. Key trends and opportunities

7.5.2. Market size and forecast, by Product

7.5.3. Market size and forecast, by Application

7.5.4. Market size and forecast, by End User

7.5.5. Market size and forecast, by country

7.5.5.1. Latin America

7.5.5.1.1. Key market trends, growth factors and opportunities

7.5.5.1.2. Market size and forecast, by Product

7.5.5.1.3. Market size and forecast, by Application

7.5.5.1.4. Market size and forecast, by End User

7.5.5.2. Middle East And Africa

7.5.5.2.1. Key market trends, growth factors and opportunities

7.5.5.2.2. Market size and forecast, by Product

7.5.5.2.3. Market size and forecast, by Application

7.5.5.2.4. Market size and forecast, by End User

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Top player positioning, 2021

9.1. Abbott Laboratories

9.1.1. Company overview

9.1.2. Key Executives

9.1.3. Company snapshot

9.1.4. Operating business segments

9.1.5. Product portfolio

9.1.6. Business performance

9.1.7. Key strategic moves and developments

9.2. ARIEL Precision Medicine, Inc.

9.2.1. Company overview

9.2.2. Key Executives

9.2.3. Company snapshot

9.2.4. Operating business segments

9.2.5. Product portfolio

9.2.6. Key strategic moves and developments

9.3. F. Hoffmann-La Roche Ltd.

9.3.1. Company overview

9.3.2. Key Executives

9.3.3. Company snapshot

9.3.4. Operating business segments

9.3.5. Product portfolio

9.3.6. Business performance

9.3.7. Key strategic moves and developments

9.4. GE Healthcare,Inc

9.4.1. Company overview

9.4.2. Key Executives

9.4.3. Company snapshot

9.4.4. Operating business segments

9.4.5. Product portfolio

9.4.6. Business performance

9.4.7. Key strategic moves and developments

9.5. Aadi Bioscience, Inc.

9.5.1. Company overview

9.5.2. Key Executives

9.5.3. Company snapshot

9.5.4. Operating business segments

9.5.5. Product portfolio

9.5.6. Business performance

9.5.7. Key strategic moves and developments

9.6. Illumina, Inc.

9.6.1. Company overview

9.6.2. Key Executives

9.6.3. Company snapshot

9.6.4. Operating business segments

9.6.5. Product portfolio

9.6.6. Business performance

9.6.7. Key strategic moves and developments

9.7. QIAGEN

9.7.1. Company overview

9.7.2. Key Executives

9.7.3. Company snapshot

9.7.4. Operating business segments

9.7.5. Product portfolio

9.7.6. Business performance

9.7.7. Key strategic moves and developments

9.8. Eli Lilly and Company

9.8.1. Company overview

9.8.2. Key Executives

9.8.3. Company snapshot

9.8.4. Operating business segments

9.8.5. Product portfolio

9.8.6. Business performance

9.9. Takeda Pharmaceutical Company Ltd

9.9.1. Company overview

9.9.2. Key Executives

9.9.3. Company snapshot

9.9.4. Operating business segments

9.9.5. Product portfolio

9.9.6. Business performance

9.10. Abbvie Inc

9.10.1. Company overview

9.10.2. Key Executives

9.10.3. Company snapshot

9.10.4. Operating business segments

9.10.5. Product portfolio

9.10.6. Business performanc

LIST OF TABLES

TABLE 01. GLOBAL PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 02. PERSONALIZED MEDICINE MARKET FOR PERSONALIZED MEDICINE THERAPEUTICS, BY REGION, 2021-2031 ($BILLION)

TABLE 03. GLOBAL PERSONALIZED MEDICINE THERAPEUTICS PERSONALIZED MEDICINE MARKET, BY TYPE, 2021-2031 ($BILLION)

TABLE 04. PERSONALIZED MEDICINE MARKET FOR PERSONALIZED MEDICINE DIAGNOSTICS, BY REGION, 2021-2031 ($BILLION)

TABLE 05. GLOBAL PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 06. PERSONALIZED MEDICINE MARKET FOR ONCOLOGY, BY REGION, 2021-2031 ($BILLION)

TABLE 07. PERSONALIZED MEDICINE MARKET FOR INFECTIOUS DISEASE, BY REGION, 2021-2031 ($BILLION)

TABLE 08. PERSONALIZED MEDICINE MARKET FOR NEUROLOGY OR PSYCHIATRY, BY REGION, 2021-2031 ($BILLION)

TABLE 09. PERSONALIZED MEDICINE MARKET FOR CARDIOVASCULAR, BY REGION, 2021-2031 ($BILLION)

TABLE 10. PERSONALIZED MEDICINE MARKET FOR OTHERS, BY REGION, 2021-2031 ($BILLION)

TABLE 11. GLOBAL PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 12. PERSONALIZED MEDICINE MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2021-2031 ($BILLION)

TABLE 13. PERSONALIZED MEDICINE MARKET FOR OTHERS, BY REGION, 2021-2031 ($BILLION)

TABLE 14. PERSONALIZED MEDICINE MARKET, BY REGION, 2021-2031 ($BILLION)

TABLE 15. NORTH AMERICA PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 16. NORTH AMERICA PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 17. NORTH AMERICA PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 18. NORTH AMERICA PERSONALIZED MEDICINE MARKET, BY COUNTRY, 2021-2031 ($BILLION)

TABLE 19. U.S. PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 20. U.S. PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 21. U.S. PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 22. CANADA PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 23. CANADA PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 24. CANADA PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 25. MEXICO PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 26. MEXICO PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 27. MEXICO PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 28. EUROPE PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 29. EUROPE PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 30. EUROPE PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 31. EUROPE PERSONALIZED MEDICINE MARKET, BY COUNTRY, 2021-2031 ($BILLION)

TABLE 32. GERMANY PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 33. GERMANY PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 34. GERMANY PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 35. FRANCE PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 36. FRANCE PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 37. FRANCE PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 38. UK PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 39. UK PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 40. UK PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 41. ITALY PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 42. ITALY PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 43. ITALY PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 44. SPAIN PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 45. SPAIN PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 46. SPAIN PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 47. REST OF EUROPE PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 48. REST OF EUROPE PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 49. REST OF EUROPE PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 50. ASIA-PACIFIC PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 51. ASIA-PACIFIC PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 52. ASIA-PACIFIC PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 53. ASIA-PACIFIC PERSONALIZED MEDICINE MARKET, BY COUNTRY, 2021-2031 ($BILLION)

TABLE 54. JAPAN PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 55. JAPAN PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 56. JAPAN PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 57. CHINA PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 58. CHINA PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 59. CHINA PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 60. AUSTRALIA PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 61. AUSTRALIA PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 62. AUSTRALIA PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 63. REST OF ASIA-PACIFIC PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 64. REST OF ASIA-PACIFIC PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 65. REST OF ASIA-PACIFIC PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 66. LAMEA PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 67. LAMEA PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 68. LAMEA PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 69. LAMEA PERSONALIZED MEDICINE MARKET, BY COUNTRY, 2021-2031 ($BILLION)

TABLE 70. LATIN AMERICA PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 71. LATIN AMERICA PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 72. LATIN AMERICA PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 73. MIDDLE EAST AND AFRICA PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021-2031 ($BILLION)

TABLE 74. MIDDLE EAST AND AFRICA PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021-2031 ($BILLION)

TABLE 75. MIDDLE EAST AND AFRICA PERSONALIZED MEDICINE MARKET, BY END USER, 2021-2031 ($BILLION)

TABLE 76. ABBOTT LABORATORIES: KEY EXECUTIVES

TABLE 77. ABBOTT LABORATORIES: COMPANY SNAPSHOT

TABLE 78. ABBOTT LABORATORIES: PRODUCT SEGMENTS

TABLE 79. ABBOTT LABORATORIES: PRODUCT PORTFOLIO

TABLE 80. ABBOTT LABORATORIES: KEY STRATERGIES

TABLE 81. ARIEL PRECISION MEDICINE, INC.: KEY EXECUTIVES

TABLE 82. ARIEL PRECISION MEDICINE, INC.: COMPANY SNAPSHOT

TABLE 83. ARIEL PRECISION MEDICINE, INC.: PRODUCT SEGMENTS

TABLE 84. ARIEL PRECISION MEDICINE, INC.: PRODUCT PORTFOLIO

TABLE 85. ARIEL PRECISION MEDICINE, INC.: KEY STRATERGIES

TABLE 86. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES

TABLE 87. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT

TABLE 88. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS

TABLE 89. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO

TABLE 90. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES

TABLE 91. GE HEALTHCARE,INC: KEY EXECUTIVES

TABLE 92. GE HEALTHCARE,INC: COMPANY SNAPSHOT

TABLE 93. GE HEALTHCARE,INC: PRODUCT SEGMENTS

TABLE 94. GE HEALTHCARE,INC: PRODUCT PORTFOLIO

TABLE 95. GE HEALTHCARE,INC: KEY STRATERGIES

TABLE 96. AADI BIOSCIENCE, INC.: KEY EXECUTIVES

TABLE 97. AADI BIOSCIENCE, INC.: COMPANY SNAPSHOT

TABLE 98. AADI BIOSCIENCE, INC.: PRODUCT SEGMENTS

TABLE 99. AADI BIOSCIENCE, INC.: PRODUCT PORTFOLIO

TABLE 100. AADI BIOSCIENCE, INC.: KEY STRATERGIES

TABLE 101. ILLUMINA, INC.: KEY EXECUTIVES

TABLE 102. ILLUMINA, INC.: COMPANY SNAPSHOT

TABLE 103. ILLUMINA, INC.: PRODUCT SEGMENTS

TABLE 104. ILLUMINA, INC.: PRODUCT PORTFOLIO

TABLE 105. ILLUMINA, INC.: KEY STRATERGIES

TABLE 106. QIAGEN: KEY EXECUTIVES

TABLE 107. QIAGEN: COMPANY SNAPSHOT

TABLE 108. QIAGEN: PRODUCT SEGMENTS

TABLE 109. QIAGEN: PRODUCT PORTFOLIO

TABLE 110. QIAGEN: KEY STRATERGIES

TABLE 111. ELI LILLY AND COMPANY: KEY EXECUTIVES

TABLE 112. ELI LILLY AND COMPANY: COMPANY SNAPSHOT

TABLE 113. ELI LILLY AND COMPANY: PRODUCT SEGMENTS

TABLE 114. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO

TABLE 115. TAKEDA PHARMACEUTICAL COMPANY LTD: KEY EXECUTIVES

TABLE 116. TAKEDA PHARMACEUTICAL COMPANY LTD: COMPANY SNAPSHOT

TABLE 117. TAKEDA PHARMACEUTICAL COMPANY LTD: SERVICE SEGMENTS

TABLE 118. TAKEDA PHARMACEUTICAL COMPANY LTD: PRODUCT PORTFOLIO

TABLE 119. ABBVIE INC: KEY EXECUTIVES

TABLE 120. ABBVIE INC: COMPANY SNAPSHOT

TABLE 121. ABBVIE INC: PRODUCT SEGMENTS

TABLE 122. ABBVIE INC: PRODUCT PORTFOLIO LIST OF FIGURES

FIGURE 01. PERSONALIZED MEDICINE MARKET, 2021-2031

FIGURE 02. SEGMENTATION OF PERSONALIZED MEDICINE MARKET, 2021-2031

FIGURE 03. TOP INVESTMENT POCKETS IN PERSONALIZED MEDICINE MARKET (2022-2031)

FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS

FIGURE 05. LOW BARGAINING POWER OF BUYERS

FIGURE 06. LOW THREAT OF SUBSTITUTES

FIGURE 07. LOW THREAT OF NEW ENTRANTS

FIGURE 08. LOW INTENSITY OF RIVALRY

FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALPERSONALIZED MEDICINE MARKET

FIGURE 10. PERSONALIZED MEDICINE MARKET, BY PRODUCT, 2021(%)

FIGURE 11. COMPARATIVE SHARE ANALYSIS OF PERSONALIZED MEDICINE MARKET FOR PERSONALIZED MEDICINE THERAPEUTICS, BY COUNTRY 2021 AND 2031(%)

FIGURE 12. COMPARATIVE SHARE ANALYSIS OF PERSONALIZED MEDICINE MARKET FOR PERSONALIZED MEDICINE DIAGNOSTICS, BY COUNTRY 2021 AND 2031(%)

FIGURE 13. PERSONALIZED MEDICINE MARKET, BY APPLICATION, 2021(%)

FIGURE 14. COMPARATIVE SHARE ANALYSIS OF PERSONALIZED MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY 2021 AND 2031(%)

FIGURE 15. COMPARATIVE SHARE ANALYSIS OF PERSONALIZED MEDICINE MARKET FOR INFECTIOUS DISEASE, BY COUNTRY 2021 AND 2031(%)

FIGURE 16. COMPARATIVE SHARE ANALYSIS OF PERSONALIZED MEDICINE MARKET FOR NEUROLOGY OR PSYCHIATRY, BY COUNTRY 2021 AND 2031(%)

FIGURE 17. COMPARATIVE SHARE ANALYSIS OF PERSONALIZED MEDICINE MARKET FOR CARDIOVASCULAR, BY COUNTRY 2021 AND 2031(%)

FIGURE 18. COMPARATIVE SHARE ANALYSIS OF PERSONALIZED MEDICINE MARKET FOR OTHERS, BY COUNTRY 2021 AND 2031(%)

FIGURE 19. PERSONALIZED MEDICINE MARKET, BY END USER, 2021(%)

FIGURE 20. COMPARATIVE SHARE ANALYSIS OF PERSONALIZED MEDICINE MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY 2021 AND 2031(%)

FIGURE 21. COMPARATIVE SHARE ANALYSIS OF PERSONALIZED MEDICINE MARKET FOR OTHERS, BY COUNTRY 2021 AND 2031(%)

FIGURE 22. PERSONALIZED MEDICINE MARKET BY REGION, 2021

FIGURE 23. U.S. PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)

FIGURE 24. CANADA PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)

FIGURE 25. MEXICO PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)

FIGURE 26. GERMANY PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)

FIGURE 27. FRANCE PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)

FIGURE 28. UK PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)

FIGURE 29. ITALY PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)

FIGURE 30. SPAIN PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)

FIGURE 31. REST OF EUROPE PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)

FIGURE 32. JAPAN PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)

FIGURE 33. CHINA PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)

FIGURE 34. AUSTRALIA PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)

FIGURE 35. REST OF ASIA-PACIFIC PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)

FIGURE 36. LATIN AMERICA PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)

FIGURE 37. MIDDLE EAST AND AFRICA PERSONALIZED MEDICINE MARKET, 2021-2031 ($BILLION)

FIGURE 38. TOP WINNING STRATEGIES, BY YEAR

FIGURE 39. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 40. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 41. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 42. COMPETITIVE DASHBOARD

FIGURE 43. COMPETITIVE HEATMAP: PERSONALIZED MEDICINE MARKET

FIGURE 44. TOP PLAYER POSITIONING, 2021

FIGURE 45. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)

FIGURE 46. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 47. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 48. F. HOFFMANN-LA ROCHE LTD.: NET SALES, 2020-2022 ($MILLION)

FIGURE 49. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2021 (%)

FIGURE 50. GE HEALTHCARE,INC: NET REVENUE, 2019-2021 ($MILLION)

FIGURE 51. GE HEALTHCARE,INC: REVENUE SHARE BY SEGMENT, 2021 (%)

FIGURE 52. GE HEALTHCARE,INC: REVENUE SHARE BY REGION, 2021 (%)

FIGURE 53. AADI BIOSCIENCE, INC.: NET REVENUE, 2020-2021 ($MILLION)

FIGURE 54. ILLUMINA, INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 55. ILLUMINA, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 56. ILLUMINA, INC.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 57. QIAGEN: NET REVENUE, 2019-2021 ($MILLION)

FIGURE 58. QIAGEN: REVENUE SHARE BY SEGMENT, 2021 (%)

FIGURE 59. QIAGEN: REVENUE SHARE BY REGION, 2021 (%)

FIGURE 60. ELI LILLY AND COMPANY: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 61. ELI LILLY AND COMPANY: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 62. TAKEDA PHARMACEUTICAL COMPANY LTD: NET REVENUE, 2019-2021 ($MILLION)

FIGURE 63. TAKEDA PHARMACEUTICAL COMPANY LTD: REVENUE SHARE BY REGION, 2021 (%)

FIGURE 64. ABBVIE INC: NET REVENUE, 2019-2021 ($MILLION)

FIGURE 65. ABBVIE INC: REVENUE SHARE BY SEGMENT, 2021 (%)

FIGURE 66. ABBVIE INC: REVENUE SHARE BY REGION, 2021 (%